Epitalon Has Been Studied in Russia for Over 40 Years. The FDA Still Doesn't Trust the Data.

Complete Guide to Peptides Editorial Team

This article is provided for general informational purposes only and is not medical advice. Speak to a qualified healthcare professional before making any decisions about peptide use.

Epitalon isn’t a new discovery riding a social media trend. It was developed decades ago by Russian scientist Vladimir Khavinson, who spent much of his career studying it and a family of related peptides for their effects on ageing. It’s arguably the peptide in this whole PCAC story with the longest research history behind it. And it still couldn’t get an unambiguous yes from an FDA advisory committee, only a narrow 7-5 recommendation on day two of July’s hearing, with one abstention.

That gap between “extensively studied” and “hard to get past a US regulatory panel” is the real story here.

The backstory

Epitalon, also spelled Epithalon, is a synthetic tetrapeptide, just four amino acids, modelled on Epithalamin, a substance naturally produced by the pineal gland. Khavinson’s research, and the broader Russian literature that followed it, associated the compound with telomerase activation and telomere lengthening, along with effects on melatonin regulation and circadian rhythm. That’s exactly why it’s become a fixture in longevity and anti-ageing circles: the pitch is directly about slowing cellular ageing, not just recovery or performance.

What was actually being proposed

The nomination in front of PCAC covered Epitalon in both its free base and acetate forms, for compounding tied to the anti-ageing and telomerase-related uses the compound is known for. FDA’s evaluation looked at whether the substance was well enough characterised and whether the safety and effectiveness evidence supported adding it to the 503A list.

Where the evidence actually stands

Here’s the tension. Independent sources reviewing Epitalon’s safety profile generally describe it as one of the better-tolerated peptides in the broader “bioregulator” category Khavinson’s work belongs to, with good general tolerability reported across most patients. That’s a genuinely more reassuring picture than several of the other six peptides in this story.

The catch is where that evidence actually comes from. It’s predominantly Russian in origin, and it hasn’t seen much independent replication outside that body of work. FDA’s briefing document raised the same concerns here that it raised across the other six compounds: gaps in characterisation, and insufficient data specifically generated or validated in a way that meets the agency’s evidentiary standard, regardless of how long the compound has been studied elsewhere.

That’s worth sitting with for a moment, because it cuts against the instinct that “decades of use” automatically means “well-established safety.” Decades of use in one research tradition, without independent replication in the systems FDA relies on, isn’t the same thing, and the agency treated it accordingly.

The vote

Epitalon passed 7-5 with one abstention, on day two of the hearing, in the same session as Semax and the sole rejection, Emideltide. It’s a narrower margin than the 8-6 splits that carried BPC-157, TB-500 and KPV through on day one, and roughly in line with MOTS-c’s 7-5 result, though for a different reason. Where MOTS-c’s file was thin because almost nothing existed, Epitalon’s issue was closer to an evidence-provenance problem: plenty of research exists, but not in a form the committee could fully rely on.

What actually changes today

Nothing, and this is worth repeating for every peptide in this series: a PCAC recommendation isn’t a rule. Epitalon isn’t on the 503A Bulks List. Before that changes, FDA has to decide whether to act on the recommendation, publish a proposed rule, take public comment, and finalise it, a process that realistically takes eight months to two years. Epitalon is also not FDA-approved for any use, and nothing here changes that either.

Given the specific nature of FDA’s concern, an evidence base that exists but hasn’t been independently validated, it’s plausible that future rulemaking on Epitalon focuses on requiring replication studies rather than starting from scratch on safety, which would put it in a slightly different position to a compound like MOTS-c going forward.

Until any of that plays out, Epitalon remains available only through the research peptide market, and sourcing from a supplier who actually tests and documents what they sell matters more than most marketing claims about “40 years of research” might suggest. Complete Peptides is where we’d point researchers looking for that kind of transparency.

We’ll update this page once the FDA responds formally to the July recommendation.

More information

Dosage and Protocol

Clinical trials tested doses ranging from 250mcg to 1mg daily, with most protocols settling around 300 to 500mcg for optimal fat metabolism support — six clinical trials involving over 900 participants established this window through systematic dose-finding studies. Audible

The research community protocol broadly aligns with this clinical range — with subcutaneous injection producing the most reliable and consistent results.

Standard Research Protocol:

Daily dose: 300 to 500mcg once daily
Timing: Morning administration in a fasted state — AOD-9604 works through fat metabolism pathways that are most active in a low insulin environment
Post administration fast: At least 30 minutes before eating — ideally longer for maximum effect
Cycle length: 12 to 16 weeks, followed by a break of 4 to 8 weeks before repeating

Clinical research found no additional benefit above 1mg daily — the evidence does not support aggressive dose escalation as a route to better outcomes. Amazon

Consistency within the established range over a full 12 to 16 week cycle is far more valuable than chasing a higher dose. This is a compound that rewards patience and discipline more than ambition.

Reconstitution & Mixing Guide

Understanding how to reconstitute your peptide correctly is as important as knowing the right dose — because the volume of bacteriostatic water you add to the vial directly determines the concentration of every injection you draw. Getting this wrong means either consistently underdosing or overdosing without realising it — which is why this section sits alongside the dosage guidance rather than in a separate guide.

The Basic Principle

AOD-9604 comes as lyophilised powder in a sealed vial — most commonly in amounts of 2mg, 5mg or 10mg. Bacteriostatic water is added to dissolve the powder and create a solution that can be drawn into an insulin syringe for subcutaneous administration. The amount of water you add determines the concentration — and therefore how many units on your insulin syringe correspond to your target dose.

More water = weaker concentration = more units per dose Less water = stronger concentration = fewer units per dose

Neither is right or wrong — what matters is that you know exactly what concentration you have mixed so every injection is accurate.

For AOD-9604 — Practical Mixing Examples

Using a standard 5mg (5,000mcg) vial as the reference:

Add 1ml of bacteriostatic water:

Concentration = 5,000mcg per ml
Each unit on a 100-unit insulin syringe = 50mcg
A 300mcg dose = 6 units
A 500mcg dose = 10 units

Add 2ml of bacteriostatic water (most commonly used ratio):

Concentration = 2,500mcg per ml
Each unit on a 100-unit insulin syringe = 25mcg
A 300mcg dose = 12 units
A 500mcg dose = 20 units

Add 3ml of bacteriostatic water:

Concentration = 1,666mcg per ml
Each unit on a 100-unit insulin syringe = 16.66mcg
A 300mcg dose = 18 units
A 500mcg dose = 30 units

For most people adding 2ml to a 5mg vial creates the most practical working concentration — the numbers are straightforward to calculate and the volume per injection is comfortable for subcutaneous administration.

How to Reconstitute Correctly

When adding bacteriostatic water to the vial, inject the water slowly down the inside wall of the vial rather than directly onto the peptide powder. Never shake the vial — shaking can degrade the peptide chain and reduce potency. Instead, gently swirl the vial until the powder is fully dissolved. The solution should be clear and colourless — if it appears cloudy or contains particles do not use it.

Storage After Reconstitution

Once reconstituted, AOD-9604 should be stored in the refrigerator at 2 to 8 degrees Celsius. Do not freeze a reconstituted vial. Stored correctly, a reconstituted solution is typically stable for 28 to 30 days. Always use bacteriostatic water rather than standard sterile water for multi-dose vials — the benzyl alcohol preservative is what allows the solution to remain stable and safe across multiple uses.

Supporting Supplements

The supplements that best support AOD-9604’s effects are those that complement fat metabolism and maintain the cellular environment in which lipolysis operates most effectively.

L-Carnitine deserves the top spot here — it plays a direct role in transporting fatty acids into the mitochondria where they are burned for energy. In the context of a compound that stimulates the release of fat from fat cells, L-Carnitine supports the completion of that process — ensuring released fatty acids are efficiently oxidised rather than redeposited. The combination of AOD-9604 initiating lipolysis and L-Carnitine supporting oxidation is one of the most coherent supplement pairings in the body composition space.

Magnesium supports the enzymatic processes involved in fat metabolism and energy production — maintaining the cellular environment in which AOD-9604’s mechanisms operate most effectively.

Vitamin D maintains the hormonal and metabolic environment in which body composition interventions produce the most meaningful results — particularly relevant given widespread deficiency in the UK population.

Zinc supports the metabolic and hormonal processes that influence body composition — including testosterone and thyroid function, both of which have meaningful relationships with fat metabolism.

A quality multivitamin provides the broad micronutrient support that cellular fat metabolism requires — including the B vitamins directly involved in energy production pathways.

Foods That Complement AOD-9604

The nutritional approach during an AOD-9604 protocol focuses on supporting the fat metabolism mechanism while protecting the fasted morning window in which the compound operates most effectively.

The pre-administration morning fast should be kept clean — black coffee is acceptable, but anything containing calories triggers an insulin response that directly reduces the lipolytic activity AOD-9604 is designed to promote. This is one of the most important and most frequently overlooked aspects of getting the most from this compound.

Through the rest of the day the nutritional approach that best supports AOD-9604’s effects centres on lean protein at every meal — protecting and building lean tissue while the compound targets fat. Healthy fats, high fibre vegetables and reduced refined carbohydrates create the stable blood sugar and anti-inflammatory metabolic environment in which the compound works most effectively.

Oily fish two to three times per week delivers omega-3 fatty acids that support both the anti-inflammatory environment and the cardiovascular system — particularly relevant given that AOD-9604 is releasing fatty acids into circulation during its active window. Ultra-processed foods, refined sugars and alcohol disrupt insulin sensitivity and the fat oxidation pathways the compound is working to support — worth minimising throughout the protocol period.

Lifestyle Considerations

Exercise timing is one of the most practical optimisations available to anyone using AOD-9604. The compound’s lipolytic effect — releasing fatty acids from fat cells into the bloodstream — creates an ideal pre-exercise environment. Scheduling training after the morning fasted administration window allows those released fatty acids to be used as fuel during the session. AOD-9604 initiates lipolysis — exercise provides the demand that burns what has been released. That combination is significantly more effective than either in isolation.

Resistance training is particularly valuable alongside AOD-9604 for the active population this compound tends to attract — preserving and building lean tissue while the compound targets adipose tissue produces the body composition shift that most people using it are actually looking for.

Consistency is the variable that matters most with AOD-9604. Daily administration over a full 12 to 16 week cycle builds cumulative benefit in a way that intermittent use simply does not. The compound rewards a disciplined and consistent approach above everything else.

Sleep quality and stress management both influence the hormonal environment in which fat metabolism operates — elevated cortisol from poor sleep or chronic stress directly impairs lipolysis and works against the mechanism AOD-9604 is supporting.

Peptide Pairing

AOD-9604 pairs naturally with compounds that complement its targeted fat metabolism approach from different angles and timing windows.

CJC-1295 with Ipamorelin in a pre-sleep protocol is the most popular and well-reasoned pairing — growth hormone release during sleep complements daytime fat metabolism support from AOD-9604, addressing body composition across two distinct timing windows and two complementary mechanisms. Many active people running a body composition protocol use this combination as their core stack.

5-Amino-1MQ is an interesting complementary pairing — working on fat cell metabolism through NNMT enzyme inhibition while AOD-9604 works through beta-3 adrenergic pathways. The two mechanisms are genuinely distinct and potentially additive for someone whose primary focus is body composition optimisation.

TB-500 is commonly used alongside AOD-9604 by active individuals in training — supporting tissue repair and recovery while AOD-9604 addresses the body composition side of the protocol. For someone training hard during a body composition phase this combination covers both performance and physique goals simultaneously.

BPC-157 supports gut health and overall recovery — relevant for anyone whose training intensity during a body composition protocol creates additional physiological demand.

Realistic Expectations

For the right person — active, training consistently, eating well and looking for precision body composition support — AOD-9604 delivers genuine and noticeable results. Changes in body composition, particularly in the areas of stubborn adipose tissue that tend to resist lifestyle interventions alone, are typically noticeable within 4 to 8 weeks of consistent daily injectable use alongside exercise and good nutrition.

It is not a dramatic weight loss compound and it does not need to be — that is simply not what it was designed for. What it is designed for, it does with a selectivity and tolerability that few compounds in this space can match. Its safety profile across six clinical trials involving over 900 participants is excellent — no significant adverse effects have been identified within the established dosing range. Audible

Used consistently, in the morning fasted window, alongside regular training and a well-structured nutritional approach — AOD-9604 is a genuinely valuable precision tool. For the person it is designed for, it works.